Lewis KD, Peris K, Sekulic A, Stratigos AJ, Dunn L, Eroglu Z, Chang ALS, Migden MR, Yoo S-Y, Mohan K, Coates E, Okoye E, Baurain J-F, Bechter O, Hauscild A, Butler MO, Hernandez-Aya L, Licitra L, Neves RI, Ruiz ES, Seebach F, Lowy I, Goncalves P, Fury MG. Primary analysis of Phase 2 results for cemiplimab in patients with metastatic basal cell carcinoma who progressed on or were intolerant to hedgehog inhibitors. J of Skin [Internet]. 2023 Mar. 13 [cited 2024 Jul. 4];7(2):s177. Available from: https://jofskin.org/33014/index.php/skin/article/view/2002